The DOI matches its Crossref record; 144 of the 145 references it cites were found in a registry or an index; none of the 80 sources its claims cite is checked for support yet.
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Open accessAbstract
Cancer metabolism has long been equated with aerobic glycolysis, seen by early biochemists as primitive and inefficient. Despite these early beliefs, the metabolic signatures of cancer cells are not passive responses to damaged mitochondria, but result from oncogene-directed metabolic reprogramming required to support anabolic growth. Recent evidence suggests that metabolites themselves can be oncogenic by altering cell signaling and blocking cellular differentiation. No longer can cancer-associated alterations in metabolism be viewed as an indirect response to cell proliferation and survival signals. We contend that altered metabolism has attained the status of a core hallmark of cancer.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review argues that metabolic reprogramming is a core hallmark of cancer, driven by oncogenes and tumor suppressors to support anabolic growth rather than arising passively from mitochondrial damage. It highlights mitochondrial biosynthetic roles, PKM2 and other metabolic enzyme alterations, and oncometabolites such as 2HG that can disrupt epigenetics and differentiation.
Key findings
- Altered metabolism is not merely a secondary response to proliferation signals; it results from active reprogramming by oncogenes and tumor suppressors and is selected during tumorigenesis. Most tumor mitochondria are not defective in oxidative phosphorylation, contrary to Warburg’s original hypothesis.
- PI3K/Akt/mTORC1 and Myc reprogram mitochondrial metabolism for biosynthesis: Akt activates ACL to divert mitochondrial citrate to acetyl-CoA, mTORC1 promotes mitochondrial biogenesis and SREBP-mediated lipogenesis, and Myc enhances glutaminase expression and glutamine addiction. HIF-1 can inhibit PDH via PDK1, blocking glucose carbon entry into mitochondrial citrate and correlating with anti-proliferative effects in some contexts.
- PKM2 is the predominant pyruvate kinase isoform in embryonic tissues and all cancer cells examined to date; it has intrinsically lower enzymatic activity than PKM1 and is sensitive to tyrosine kinase inhibition, proposed to facilitate shunting of glycolytic intermediates into anabolic pathways. At least 11 proteins have been reported to bind PKM2.
- IDH1/IDH2 mutations produce the oncometabolite 2HG, which inhibits α-ketoglutarate-dependent dioxygenases including TET enzymes and histone demethylases, altering DNA and histone methylation and impairing differentiation. IDH2 R140 mutations now account for nearly half of all cases of D-2HG aciduria; succinate and fumarate are also described as oncometabolites.
Methods
- Design: Review article; no primary experimental design is reported.
- Data or sample: Not stated in the paper as a primary dataset; the text synthesizes cited studies across cancer metabolism, oncogene/tumor suppressor signaling, metabolic enzyme isoforms, and oncometabolite biology.
- Main analysis: Conceptual and literature-based synthesis arguing that metabolic reprogramming should be considered a core cancer hallmark.
Limitations
- The paper states that current methods cannot reliably distinguish cytosolic metabolites from mitochondrial and other compartmentalized pools; fractionation methods often cause metabolite leakage, and distinct metabolite pools may exist due to enzyme channeling.
- The paper states that quantitative measurement of metabolic flux remains challenging, including obstacles such as cellular compartmentalization and reliance on complex, incompletely defined cell culture media.
- The paper states that non-cell autonomous effects of tumor metabolism are an emerging challenge, including lactate acidification, possible symbiosis between lactate-producing and lactate-consuming cells, and fatty acid exchange between omental adipocytes and ovarian carcinoma cells. The text also makes evident that unresolved issues remain, such as conflicting conclusions over whether reductive glutamine flux depends primarily on cytosolic IDH1 or mitochondrial IDH2, the role of 2HG in PHD2/HIF regulation, and which alternative NADPH-generating pathways are most important.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 80 cited sources checked · 0 supported · 0 flagged
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Evidence is also developing for the proposal that proto-oncogenes and tumor suppressors primarily evolved to regulate metabolism.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Introduction
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We contend that altered metabolism has attained the status of a core hallmark of cancer.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Abstract
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes? Checkable: unclear✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite these early beliefs, the metabolic signatures of cancer cells are not passive responses to damaged mitochondria, but result from oncogene-directed metabolic reprogramming required to support anabolic growth.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearNone of the sources cited for this claim have been checked yet.
In the paper
“Activated PI3K/Akt leads to enhanced glucose uptake and glycolysis (Buzzai et al., 2005; Elstrom et al., 2004).”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > PI3K/Akt/mTORC1 activation: driving anabolic metabolism and tumorigenesis by reprogramming mitochondria
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In fact, most cancer cells and proliferating normal cells still derive a significant fraction of their ATP through oxidative phosphorylation.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Altered metabolism is a direct response to growth factor signaling
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Recent evidence suggests that metabolites themselves can be oncogenic by altering cell signaling and blocking cellular differentiation.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Rather than ATP, proliferating cells are in much greater need of reduced carbon and reduced nitrogen, as well as cytosolic NADPH for reductive biosynthetic reactions.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Altered metabolism is a direct response to growth factor signaling
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“However, in contrast to Warburg's original hypothesis, damaged mitochondria are not at the root of the aerobic glycolysis exhibited by most tumor cells.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Introduction
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this supply-based model, changes in metabolic fluxes occur in primary response to growth factor signaling, independent of changes in ATP and other mechanisms worked out by early biochemists (Figure 2B).”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Altered metabolism is a direct response to growth factor signaling
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Most tumor mitochondria are not defective in their ability to carry out oxidative phosphorylation.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Introduction
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclear
- Probably not a substantial claim. 12
- It may state two separate claims as one. 14
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Activation of the PI3K/Akt pathway is perhaps the most common lesion in spontaneous human cancers.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > PI3K/Akt/mTORC1 activation: driving anabolic metabolism and tumorigenesis by reprogramming mitochondria
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“It has become clear that anabolic metabolism is under complex regulatory control directed by growth factor signal transduction in non-transformed cells.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Introduction
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Both of these findings are consistent with PKM2 primarily acting as a glycolytic switch that can be rapidly inactivated in tumor cells by multiple mechanisms, all of which facilitate the shunting of glucose carbon/glycolytic intermediates into branching anabolic pathways.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > The primary role of PKM2 expression in proliferating cells is to facilitate anabolic metabolism
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“IDH1 mutations at R132 are not simply loss-of-function for isocitrate and α-ketoglutarate interconversion, but also acquire a novel reductive activity to convert α-ketoglutarate to 2-hydroxyglutarate (2HG)”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Oncogenic mutations in metabolic enzymes: the discovery of IDH1 mutations and the oncometabolite 2-hydroxyglutarate
What the sources say
- Not checked yetcites Dang et al., 2009 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In both cell types, the overexpression of IDH mutants blocked acquisition of mature myeloid markers while increasing the expression of stem cell markers (Figueroa et al., 2010).”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Metabolites as oncogenes: dysregulating epigenetics and cellular differentiation
What the sources say
- Not checked yetcites Figueroa et al., 2010 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Metabolite screening approaches can also distinguish neomorphic IDH mutations from SNPs and sequencing artifacts with no effect on IDH enzyme activity, as well as from an apparently rare subset of loss-of-function, non 2HG-producing IDH mutations”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > 2HG is a biomarker and common feature of both IDH1 and IDH2 mutations
What the sources say
- Not checked yetcites Ward et al., 2011
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Cells expressing oncogenic Myc are glutamine-addicted and undergo apoptosis when glutamine is withdrawn from the culture medium.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Myc activation also impacts mitochondrial metabolism
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“these data raise the possibility that significant flux through G6PD to generate NADPH is not necessarily critical for cell proliferation or tumorigenesis”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Textbook biochemical pathways often do not apply to proliferating cells
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Historically, the oxidative pentose phosphate pathway, branching off glycolysis at glucose-6-phosphate dehydrogenase (G6PD), has been considered the major NADPH producing pathway.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Textbook biochemical pathways often do not apply to proliferating cells
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“It is critical for providing reducing equivalents for fatty acid and cholesterol biosynthesis, as well as for modulating oxidative stress.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Textbook biochemical pathways often do not apply to proliferating cells
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These findings could all be correct if a mitochondrial-cytosolic NADPH shuttle exists using these enzymes (Figure 6).”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Textbook biochemical pathways often do not apply to proliferating cells
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Recent work has revisited how proliferating cells maintain glycolytic flux by either minimizing ATP production or enhancing ATP consumption.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Textbook biochemical pathways often do not apply to proliferating cells
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Perhaps elevated succinate and fumarate resulting from SDH and FH mutations can promote tumorigenesis in part through epigenetic modulation.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > 2HG is not the only oncometabolite
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“these findings provide further evidence that IDH mutation can impair differentiation in non-transformed cells from multiple cells of origin, and that this impairment is linked to 2HG-mediated epigenetic dysregulation.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > The oncometabolite 2HG does more than inhibit TET activity and DNA demethylation
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The ability of 2HG to alter epigenetics may reflect its evolutionary ancient status as a signal for elevated glutamine/glutamate metabolism and/or oxygen deficiency.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > 2HG is not the only oncometabolite
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Alternatively, other chromatin-modifying α-ketoglutarate dependent dioxygenase enzymes may be inhibited by 2HG in these cells.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > The oncometabolite 2HG does more than inhibit TET activity and DNA demethylation
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“In this alternative pathway, the high-energy phosphate of PEP is not transferred to ADP, but instead to a histidine residue on an upstream glycolytic enzyme. This alternative transfer therefore decouples the PEP→pyruvate conversion from ATP production.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Textbook biochemical pathways often do not apply to proliferating cells
What the sources say
- Not checked yetcites Vander Heiden et al., 2010
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“glycolysis in proliferating cells is limited by the rate of ATP consumption and not ATP production, as glycolytic enzymes can be inhibited when ATP levels are high (Scholnick et al., 1973)”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Textbook biochemical pathways often do not apply to proliferating cells
What the sources say
- Not checked yetcites Scholnick et al., 1973
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Even within one subcellular compartment, there may be distinct pools of metabolites resulting from channeling between metabolic enzymes.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Challenges ahead for studying the metabolic hallmark of cancer
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“many obstacles remain such as cellular compartmentalization and the reliance of most cell culture on complex, incompletely defined media.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Challenges ahead for studying the metabolic hallmark of cancer
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“we remain unable to reliably distinguish cytosolic metabolites from those in the mitochondria and other compartments. Current fractionation methods often lead to metabolite leakage.”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Challenges ahead for studying the metabolic hallmark of cancer
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“some tumors may exhibit a symbiosis between lactate-producing cells and lactate-consuming cells (Sonveaux et al., 2008)”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Challenges ahead for studying the metabolic hallmark of cancer
What the sources say
- Not checked yetcites Sonveaux et al., 2008
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“lactate produced by tumor cells can acidify the surrounding microenvironment and potentially promote tumor invasion”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Challenges ahead for studying the metabolic hallmark of cancer
What the sources say
- Not checked yetcites Sonveaux et al., 2008
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“fatty acid exchange between omental adipocytes and ovarian carcinoma cells has been documented (Nieman et al., 2011)”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Challenges ahead for studying the metabolic hallmark of cancer
What the sources say
- Not checked yetcites Nieman et al., 2011
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“critical fluxes have been quantified in cultured cancer cells and methods for these analyses continue to improve (DeBerardinis et al., 2007; Mancuso et al., 2004; Yuan et al., 2008)”
§ Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate > Challenges ahead for studying the metabolic hallmark of cancer
What the sources say
- Not checked yetcites DeBerardinis et al., 2007 source
- Not checked yetcites Mancuso et al., 2004
- Not checked yetcites Yuan et al., 2008
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The evidence for the necessity of glutamine for cancer progression is conflicted: some studies have reported that tumours can grow well without glutamine [66,67], while others showed that cancers are glutamine-addicted [68,69,70].”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [68]
In the citing paper
“The previous paradigm of metabolic regulation argued that metabolic pathways were exclusively controlled through allosteric regulation of metabolic enzymes, either by ATP levels or metabolites themselves (the reactive model) (40).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [40]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Self-citationAn Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationKim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
Otto Warburg's contributions to current concepts of cancer metabolism
Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3038 · Cited by 3,427
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Self-citation
Flagged first, then by citations
1 of the 145 references couldn’t be matched to a known paper.
Research works printed but not linked: 11
- Boros, 2000, Cancer Res., 60, 1183
- Choi, 2012, Nat Med.
- Eigenbrodt, 1983, Biomed. Biochim. Acta, 42, S278
- Ferraris, 1988, Am. J. Hum. Genet., 42, 516
- Lu, 2012, Nature
- Mazurek, 2007, Anticancer Res., 27, 3963
- Rempel, 1996, Cancer Res., 56, 2468
- Sonveaux, 2008, J. Clin. Invest., 118, 3930
- Tallal, 1970, Cancer, 25, 306, 10.1002/1097-0142(197002)25:2<306::aid-cncr2820250206>3.0.co;2-h · DOI
- Turcan, 2012, Nature
- Ward, 2011, Oncogene
Cited by
Sorted by citations
Items 301–400 of 1,011
METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism
Han, L., Dong, L., Leung, K., Zhao, Z., Li, Y.-C., Gao, L., Chen, Z.-H., Xue, J., Qing, Y., Li, W., et al. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2022.12.006 · Cited by 152
Starvation, Stress Resistance, and Cancer
Buono, R., & Longo, V. D. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.01.008 · Cited by 162
Ma, Z., & Vosseller, K. (2013) · Amino Acids · doi:10.1007/s00726-013-1543-8 · Cited by 164
Oncogenic regulation of tumor metabolic reprogramming
Tarrado‐Castellarnau, M., de Atauri, P., & Cascante, M. (2016) · Oncotarget · doi:10.18632/oncotarget.10911 · Cited by 165
Chaube, B., Malvi, P., Singh, S. V., Mohammad, N., Viollet, B., & Bhat, M. K. (2015) · Cell Death Discovery · doi:10.1038/cddiscovery.2015.63 · Cited by 162
Genetic and metabolic hallmarks of clear cell renal cell carcinoma
Sanchez, D. J., & Simon, M. C. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.003 · Cited by 164
The Role of NRF2/KEAP1 Signaling Pathway in Cancer Metabolism
Song, M.-Y., Lee, D.-Y., Chun, K., & Kim, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094376 · Cited by 170
Landscape of the mitochondrial Hsp90 metabolome in tumours
Chae, Y. C., Angelin, A., Lisanti, S., Kossenkov, A. V., Speicher, K. D., Wang, H., Powers, J. F., Tischler, A. S., Pacák, K., Fliedner, S. M. J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3139 · Cited by 162
The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis
Joshi, S., Tolkunov, D., Aviv, H., Hakimi, A. A., Yao, M., Hsieh, J. J.-D., Ganesan, S., Chan, C. S., & White, E. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.059 · Cited by 162
Mitochondria, cholesterol and cancer cell metabolism
Ribas, V., García‐Ruiz, C., & Fernández-Checa, J. C. (2016) · Clinical and Translational Medicine · doi:10.1186/s40169-016-0106-5 · Cited by 166
Wang, J., Qiu, S., Chen, S., Xiong, C., Liu, H., Wang, J., Zhang, N., Hou, J., He, Q., & Nie, Z. (2014) · Analytical Chemistry · doi:10.1021/ac504294s · Cited by 157
Yang, X., Palasuberniam, P., Kraus, D., & Chen, B. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161025865 · Cited by 158
Tsouko, E., Khan, A., White, M. A., Han, J., Shi, Y., Merchant, F. A., Sharpe, M. A., Xin, L., & Frigo, D. E. (2014) · Oncogenesis · doi:10.1038/oncsis.2014.18 · Cited by 158
Role of the Keap1–Nrf2 Pathway in Cancer
Leinonen, H. M., Kansanen, E., Pölönen, P., Heinäniemi, M., & Levonen, A. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-420117-0.00008-6 · Cited by 158
Induction of sarcomas by mutant IDH2Preprint
Lü, C., Venneti, S., Akalin, A., Fang, F., Ward, P. S., Dematteo, R. G., Intlekofer, A. M., Chen, C., Ye, J., Hameed, M., et al. (2013) · Genes & Development · doi:10.1101/gad.226753.113 · Cited by 162
Self-citationInsights into the key roles of proteoglycans in breast cancer biology and translational medicine
Theocharis, A. D., Skandalis, S. S., Neill, T., Multhaupt, H. A. B., Hubo, M., Frey, H., Gopal, S., Gomes, A. M., Afratis, N. A., Lim, H. C., et al. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.03.006 · Cited by 162
GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity
Vartanian, A., Singh, S. K., Agnihotri, S., Jalali, S., Burrell, K. E., Aldape, K., & Zadeh, G. M. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou035 · Cited by 158
Bioenergetic Adaptations in Chemoresistant Ovarian Cancer Cells
Dar, S. A., Chhina, J., Mert, İ., Chitale, D. A., Buekers, T., Kaur, H., Giri, S., Munkarah, A. R., & Rattan, R. (2017) · Scientific Reports · doi:10.1038/s41598-017-09206-0 · Cited by 160
Huber, A., Lebeau, J., Guillaumot, P., Pétrilli, V., Malek, M., Chilloux, J., Fauvet, F., Payen, L. F., Kfoury, A., Renno, T., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.009 · Cited by 169
Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma
Sangineto, M., Villani, R., Cavallone, F., Romano, A. D., Loizzi, D., & Serviddio, G. (2020) · Cancers · doi:10.3390/cancers12061419 · Cited by 153
Ou, Y., Wang, S.-J., Jiang, L., Zheng, B., & Gu, W. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.616359 · Cited by 156
Glutamate and α-ketoglutarate: key players in glioma metabolism
Maus, A., & Peters, G. J. (2016) · Amino Acids · doi:10.1007/s00726-016-2342-9 · Cited by 162
Zaytseva, Y. Y., Harris, J. W., Mitov, M. I., Kim, J. T., Butterfield, D. A., Lee, E. Y., Weiss, H. L., Gao, T., & Evers, B. M. (2015) · Oncotarget · doi:10.18632/oncotarget.3783 · Cited by 153
Small-molecule inhibitors of the Myc oncoprotein
Fletcher, S., & Prochownik, E. V. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.005 · Cited by 160
Gao, R., Cheng, J., Fan, C., Shi, X., Cao, Y., Sun, B. H., Ding, H., Hu, C., Dong, F., & Yan, X. (2015) · Scientific Reports · doi:10.1038/srep18175 · Cited by 153
Liao, M., Liao, W., Xu, N., Li, B., Liu, F., Zhang, S., Wang, Y., Wang, S., Zhu, Y., Chen, D., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.035 · Cited by 152
Teicher, B. A., Linehan, W. M., & Helman, L. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2587 · Cited by 152
The rate of glycolysis quantitatively mediates specific histone acetylation sites
Cluntun, A. A., Huang, H., Dai, L., Liu, X., Zhao, Y., & Locasale, J. W. (2015) · Cancer & Metabolism · doi:10.1186/s40170-015-0135-3 · Cited by 148
Bulusu, V., Prior, N., Snaebjornsson, M. T., Kuehne, A., Sonnen, K. F., Kress, J., Stein, F., Schultz, C., Sauer, U., & Aulehla, A. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.01.015 · Cited by 145
Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy
Bourgeois, T. L., Strauss, L., Aksoylar, H., Daneshmandi, S., Seth, P., Patsoukis, N., & Boussiotis, V. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00237 · Cited by 157
Li, Y., Xia, J., Shao, F., Zhou, Y., Yu, J., Wu, H., Du, J., & Ren, X. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.083 · Cited by 153
A new link between diabetes and cancer: enhanced WNT/β-catenin signaling by high glucose
García-Jiménez, C., García-Martínez, J. M., Chocarro-Calvo, A., & De la Vieja, A. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-13-0152 · Cited by 151
Autophagy in Cancer Stem Cells: A Potential Link Between Chemoresistance, Recurrence, and Metastasis
Ojha, R., Bhattacharyya, S., & Singh, S. K. (2015) · BioResearch open access · doi:10.1089/biores.2014.0035 · Cited by 152
Oncometabolites‐driven tumorigenesis: From genetics to targeted therapy
Morin, A., Letouzé, É., Gimenez‐Roqueplo, A., & Favier, J. (2014) · International Journal of Cancer · doi:10.1002/ijc.29080 · Cited by 162
Rosa, V. D., Iommelli, F., Monti, M., Fonti, R., Votta, G., Stoppelli, M. P., & Vecchio, S. D. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0375 · Cited by 152
Starvation and Pseudo-Starvation as Drivers of Cancer Metastasis through Translation Reprogramming
García‐Jiménez, C., & Goding, C. R. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.11.018 · Cited by 157
TMX1 determines cancer cell metabolism as a thiol-based modulator of ER–mitochondria Ca2+ flux
Raturi, A., Gutiérrez, T., Ortiz-Sandoval, C. G., Ruangkittisakul, A., Herrera-Cruz, M. S., Rockley, J. P., Gesson, K., Ourdev, D., Lou, P., Lucchinetti, E., et al. (2016) · The Journal of Cell Biology · doi:10.1083/jcb.201512077 · Cited by 154
Li, Q., Cao, L., Tian, Y., Zhang, P., Ding, C., Lu, W., Jia, C., Shao, C., Liu, W., Wang, D., et al. (2018) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.000752 · Cited by 153
Ajona, D., Ortiz‐Espinosa, S., Lozano, T., Expósito, F., Calvo, A., Valencia, K., Redrado, M., Remírez, A., Lecanda, F., Alignani, D., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0007-9 · Cited by 154
Glycolysis inhibition as a cancer treatment and its role in an anti-tumour immune response
Gill, K. S., Fernandes, P., O’Donovan, T. R., McKenna, S. L., Doddakula, K., Power, D. G., Soden, D. M., & Forde, P. F. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.06.005 · Cited by 149
Goji, T., Takahara, K., Negishi, M., & Katoh, H. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.814392 · Cited by 150
SREBP1 regulates tumorigenesis and prognosis of pancreatic cancer through targeting lipid metabolism
Sun, Y., He, W., Luo, M., Zhou, Y., Chang, G., Ren, W., Wu, K., Li, X., Shen, J., Zhao, X., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-3047-5 · Cited by 145
Canonical and non-canonical Hedgehog signalling and the control of metabolism
Teperino, R., Aberger, F., Esterbauer, H., Galdo, N. A. R., & Pospisilik, J. A. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.05.007 · Cited by 150
Oncometabolites: tailoring our genes
Nowicki, S., & Gottlieb, E. (2015) · FEBS Journal · doi:10.1111/febs.13295 · Cited by 148
N6-methyladenosine (m6A) in 18S rRNA promotes fatty acid metabolism and oncogenic transformation
Peng, H., Chen, B., Wei, W., Guo, S., Han, H., Yang, C., Ma, J., Wang, L., Peng, S., Kuang, M., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00622-9 · Cited by 147
OMA1 reprograms metabolism under hypoxia to promote colorectal cancer development
Wu, Z., Zuo, M., Zeng, L., Cui, K., Liu, B., Yan, C., Chen, L., Dong, J., Shangguan, F., Hu, W., et al. (2020) · EMBO Reports · doi:10.15252/embr.202050827 · Cited by 147
Zacksenhaus, E., Shrestha, M., Liu, J. C., Vorobieva, I., Chung, P. E. D., Ju, Y., Nir, U., & Jiang, Z. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.09.002 · Cited by 143
Protein post-translational modifications in the regulation of cancer hallmarks
Wang, H., Yang, L., Liu, M., & Luo, J. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00464-3 · Cited by 148
Cancer metabolism and carcinogenesis
Yang, J., Shay, C., Saba, N. F., & Teng, Y. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00482-x · Cited by 155
Tetracycline Antibiotics Impair Mitochondrial Function and Its Experimental Use Confounds Research
Chatzispyrou, I. A., Held, N. M., Mouchiroud, L., Auwerx, J. H., & Houtkooper, R. H. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1626 · Cited by 148
Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis
Nieminen, A. I., Eskelinen, V., Haikala, H. M., Tervonen, T. A., Yan, Y., Partanen, J. I., & Klefström, J. T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208530110 · Cited by 142
The Chaperone TRAP1 As a Modulator of the Mitochondrial Adaptations in Cancer Cells
Masgras, I., Sànchez‐Martìn, C., Colombo, G., & Rasola, A. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00058 · Cited by 143
Sormendi, S., & Wielockx, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00040 · Cited by 147
Takegahara, N., Kim, H., & Choi, Y. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01157-7 · Cited by 161
Salminen, A., Kauppinen, A., Hiltunen, M. O., & Kaarniranta, K. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.05.004 · Cited by 145
Schwartz, L. H., Seyfried, T. N., Alfarouk, K. O., Moreira, J. D. V., & Fais, S. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.01.005 · Cited by 140
Metabolic features of cancer stem cells: the emerging role of lipid metabolism
Mancini, R., Noto, A., Pisanu, M. E., Vitis, C. D., Maugeri‐Saccà, M., & Ciliberto, G. (2018) · Oncogene · doi:10.1038/s41388-018-0141-3 · Cited by 140
Yin, K., Lee, J., Liu, Z., Kim, H., Martin, D. R., Wu, D., Liu, M., & Xue, X. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00760-9 · Cited by 144
Energy Metabolism Characterization of a Novel Cancer Stem Cell‐ L ike Line 3 AB ‐ OS
Palorini, R., Votta, G., Balestrieri, C., Monestiroli, A., Olivieri, S., Vento, R., & Chiaradonna, F. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24671 · Cited by 139
Using Seahorse Machine to Measure OCR and ECAR in Cancer Cells
Zhang, J., & Zhang, Q. H. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9027-6_18 · Cited by 140
Ding, Z., Ericksen, R. E., Escande‐Beillard, N., Lee, Q. Y., Loh, A., Denil, S. L. I. J., Steckel, M., Haegebarth, A., Ho, T. S. W., Chow, P. K. H., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.026 · Cited by 138
Heuer, T. S., Ventura, R., Mordec, K., Lai, J., Fridlib, M., Buckley, D., & Kemble, G. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2016.12.012 · Cited by 136
Nokin, M., Durieux, F., Peixoto, P., Chiavarina, B., Peulen, O., Blomme, A., Turtoï, A., Costanza, B., Smargiasso, N., Baiwir, D., et al. (2016) · eLife · doi:10.7554/elife.19375 · Cited by 137
Bian, X., Chen, H., Yang, P., Li, Y.-P., Zhang, F.-N., Zhang, J.-Y., Wang, W.-J., Zhao, W., Zhang, S., Chen, Q.-T., et al. (2017) · Nature Communications · doi:10.1038/ncomms14420 · Cited by 137
SIRT3: Oncogene and Tumor Suppressor in Cancer
Torrens‐Mas, M., Oliver, J., Roca, P., & Sastre‐Serra, J. (2017) · Cancers · doi:10.3390/cancers9070090 · Cited by 138
Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling
Cruz‐Bermúdez, A., Briviesca, R. L., Vicente-Blanco, R. J., García‐Grande, A., Coronado, M. J., Laine-Menéndez, S., Alfaro, C., Sánchez, J. C., Franco, F., Calvo, V., et al. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.10.450 · Cited by 137
Vlachavas, E., Pilalis, E. D., Papadodima, O., Koczan, D., Willis, S., Klippel, S., Cheng, C., Pan, L., Sachpekidis, C., Pintzas, A., et al. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.01.007 · Cited by 137
Petan, T. (2020) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2020_51 · Cited by 145
Rani, R., & Kumar, V. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00168 · Cited by 136
mTORC2 in the center of cancer metabolic reprogramming
Masui, K., Cavenee, W. K., & Mischel, P. S. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.04.002 · Cited by 140
Integrins and Cell Metabolism: An Intimate Relationship Impacting Cancer
Ata, R., & Antonescu, C. N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010189 · Cited by 139
Dual-functional drug liposomes in treatment of resistant cancers
Mu, L.-M., Ju, R.-J., Liu, R., Bu, Y.-Z., Zhang, J., Li, X., Zeng, F., & Lü, W.-L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.006 · Cited by 136
Emergence of spatial structure in the tumor microenvironment due to the Warburg effect
Carmona‐Fontaine, C., Bucci, V., Akkari, L., Déforet, M., Joyce, J. A., & Xavier, J. B. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311939110 · Cited by 140
Diabetes and cancer: Associations, mechanisms, and implications for medical practice
Xu, C. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i3.372 · Cited by 138
Mitochondrial fission‐fusion as an emerging key regulator of cell proliferation and differentiation
Mitra, K. (2013) · BioEssays · doi:10.1002/bies.201300011 · Cited by 134
Zhou, L., Wang, Y., Zhou, M., Zhang, Y., Wang, P., Li, X., Yang, J., Wang, H., & Ding, Z. (2018) · Nature Communications · doi:10.1038/s41467-018-03914-5 · Cited by 133
Foster, D. A., Salloum, D., Menon, D., & Frías, M. A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.566091 · Cited by 131
Metabolic Vulnerabilities in Endometrial Cancer
Byrne, F. L., Poon, I. K. H., Modesitt, S. C., Tomsig, J. L., Chow, J. D. Y., Healy, M. E., Baker, W. D. C., Atkins, K. A., Lancaster, J. M., Marchion, D. C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0254 · Cited by 134
Metabolic Associations of Reduced Proliferation and Oxidative Stress in Advanced Breast Cancer
Jerby‐Arnon, L., Wolf, L., Denkert, C., Stein, G. Y., Hilvo, M., Orešič, M., Geiger, T., & Ruppin, E. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2215 · Cited by 135
Nanomedicine-mediated cancer stem cell therapy
Shen, S., Xia, J., & Wang, J. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.09.037 · Cited by 132
Tohme, S. T., Yazdani, H. O., Liu, Y., Loughran, P., van der Windt, D. J., Huang, H., Simmons, R. L., Shiva, S., Tai, S., & Tsung, A. (2017) · Hepatology · doi:10.1002/hep.29184 · Cited by 136
Fructose 2,6-Bisphosphate in Cancer Cell Metabolism
Bartrons, R., Simon‐Molas, H., Rodríguez‐García, A., Castaño, E., Navarro‐Sabaté, À., Manzano, À., & Martinez‐Outschoorn, U. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00331 · Cited by 136
Gatto, F., Nookaew, I., & Nielsen, J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319196111 · Cited by 132
Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer
Coothankandaswamy, V., Cao, S., Xu, Y., Prasad, P. D., Singh, P. K., Reynolds, C. P., Yang, S., Ogura, J., Ganapathy, V., & Bhutia, Y. D. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13616 · Cited by 132
Zheng, Z.-N., Zhang, J.-X., Jiang, J., He, Y., Zhang, W.-Y., Mo, X.-P., Kang, X.-J., Xu, Q., Wang, B., & Huang, Y.-Z. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000207 · Cited by 116
Dai, W., Xu, Y., Mo, S., Li, Q., Yu, J., Wang, R., Ma, Y., Ni, Y., Xiang, W., Han, L., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00220-9 · Cited by 135
Metabolic communication in tumors: a new layer of immunoregulation for immune evasion
Ho, P.-C., & Liu, P.-S. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0109-1 · Cited by 124
Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer
Galluzzi, L., Vitale, I., Senovilla, L., Olaussen, K. A., Pinna, G., Eisenberg, T., Goubar, A., Martins, I., Michels, J., Kratassiouk, G., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.06.017 · Cited by 137
Metabolic Reprogramming in Brain Tumors
Venneti, S., & Thompson, C. B. (2017) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044329 · Cited by 139
Self-citationSalem, A. F., Whitaker‐Menezes, D., Howell, A., Sotgia, F., & Lisanti, M. P. (2012) · Cell Cycle · doi:10.4161/cc.22376 · Cited by 131
Chinopoulos, C., & Seyfried, T. N. (2018) · ASN NEURO · doi:10.1177/1759091418818261 · Cited by 130
Siu, M. K. Y., Jiang, Y., Wang, J., Leung, T., Han, C. Y., Tsang, B. K., Cheung, A., Ngan, H., & Chan, K. K. L. (2019) · Cancers · doi:10.3390/cancers11060813 · Cited by 135
Mitochondrial oxidative phosphorylation TRAP(1)ped in tumor cells
Rasola, A., Neckers, L., & Picard, D. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.03.005 · Cited by 129
Effects of short-term fasting on cancer treatment
de Groot, S., Pijl, H., van der Hoeven, J. J. M., & Kroep, J. R. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1189-9 · Cited by 134
Altered lipid metabolism marks glioblastoma stem and non-stem cells in separate tumor niches
Shakya, S., Gromovsky, A. D., Hale, J. S., Knudsen, A. M., Prager, B. C., Wallace, L. C., Penalva, L. O. F., Ivanova, P. T., Brown, H. A., Kristensen, B. W., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01205-7 · Cited by 129
O'Hara, R., Tedone, E., Ludlow, A., Huang, E., Arosio, B., Mari, D., & Shay, J. W. (2019) · Genome Research · doi:10.1101/gr.250480.119 · Cited by 121
Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells
Cai, Q., Yan, L., & Xu, Y. (2014) · Oncogene · doi:10.1038/onc.2014.264 · Cited by 127
Colorectal Cancer and Metabolism
Brown, R. E., Short, S. P., & Williams, C. S. (2018) · Current Colorectal Cancer Reports · doi:10.1007/s11888-018-0420-y · Cited by 129
Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors
Lee, M., Hirpara, J. L., Eu, J. Q., Sethi, G., Wang, L., Goh, B.-C., & Wong, A. L. A. (2018) · Redox Biology · doi:10.1016/j.redox.2018.101073 · Cited by 129
What is pH regulation, and why do cancer cells need it?
Swietach, P. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-09778-x · Cited by 136
Metadata
- Authors
- Ward, P. S., & Thompson, C. B.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Thompson, Craig B.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 21
- Issue
- 3
- Pages
- 297-308
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC3311998
- OpenAlex
- W2052543023
- Semantic Scholar
- 9802ecaa29613434cd7f6f7fa0e72b84a26c9d29
- Cited by
- 3,233
- References
- 145
- Citations by year
- 2026: 149 · 2025: 170 · 2024: 216 · 2023: 204 · 2022: 269 · 2021: 271 · 2020: 295 · 2019: 244 · 2018: 256 · 2017: 235 · 2016: 213 · 2015: 248 · 2014: 228 · 2013: 169 · 2012: 63
- FWCI
- 17.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 994 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Pennsylvania
- National Institutes of Health
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- cancer metabolism, metabolic reprogramming, aerobic glycolysis, Warburg effect, anabolic metabolism, signal transduction, cell differentiation, cancer hallmarks, mitochondrial damage
- MeSH terms
- Cell Differentiation, Humans, Isoenzymes, Mitochondria, Models, Biological, Neoplasms, Biomarkers, Tumor, Signal Transduction, Proto-Oncogene Proteins c-myc, Alternative Splicing, Evolution, Molecular, Epigenesis, Genetic, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
